CJC-1295 acetate, Inhibitor | CJC-1295, inhibitor

CJC-1295 acetate (863288-34-0 free base)

Cat. Num. AAA5765546

• Purity: 0.98
• Synonyms: CJC-1295 acetate; CJC-1295 acetate (863288-34-0 free base); DAC:GRF acetate; CJC-1295; inhibitor

• Purity/Purification: 0.98
• Form/Format: Solid

• Solubility: DMSO: 10mM; (<1mg/ml refers to the product slightly soluble or insoluble)
• SMILES: CC[C@@H]([C@H](NC([C@@H](NC([C@@H](NC([C@H](NC([C@@H](N)CC1=CC=C(O)C=C1)=O)C)=O)CC(O)=O)=O)C)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CCCNC(N)=N)=O)CO)=O)CC(C)C)=O)[C@H](CC)C)=O)CC(O)=O)=O)CCC(N)=O)=O)CC(C)C)=O)CC(C)C)=O)CCCCN)=O)CCCNC(N)=N)=O)C)=O)CO)=O)CC(C)C)=O)CCC(N)=O)=O)C)=O)CC(C)C)=O)C(C)C)=O)CCCCN)=O)CCCNC(N)=N)=O)CC2=CC=C(O)C=C2)=O)CO)=O)CCC(N)=O)=O)[C@H](O)C)=O)CC3=CC=CC=C3)=O)C.CC(O)=O
• Formula: C154H256N44O44
• In vitro: CJC-1295 markedly increases plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in both animals and humans.[1] With a single injection, in human subjects, CJC-1295 increases plasma GH levels by 2- to 10-fold for 6 days or longer and plasma IGF-1 levels by 0.5- to 3-fold for 9 to 11 days.[3] The drug has an estimated half-life of about 6 to 8 days in humans.[3] With multiple doses of CJC-1295, IGF-1 levels were found to remain elevated in humans for up to 28 days
• Preparation and Storage: Store at 0-4 degree C for short term (days to weeks), or -20 degree C for long term (months).

Chemical Structure

Related Product Information for CJC-1295, inhibitor

CJC-1295 acetate is a synthetic analogue of growth hormone-releasing hormone (GHRH)(also known as growth hormone-releasing factor (GRF)) and a growth hormone secretagogue (GHS)

Product Categories/Family for CJC-1295, inhibitor

GPCR/G Protein; GHSR

References

Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. (July 2005). "Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog". Endocrinology. 146 (7): 3052-8.
Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R (December 2006). "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse". American Journal of Physiology. Endocrinology and Metabolism. 291 (6): E1290-4
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (March 2006). "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults". The Journal of Clinical Endocrinology and Metabolism. 91 (3): 799-805.